Experimental human RSV infection bridges pre-clinical models and clinical trials. RSV challenge allows early proof-of-concept efficacy assessment. Sampling of RSV-infected lung permits novel insights into mucosal immunity. Understanding of respiratory mucosal immune correlates directs vaccine development. Cooperation between academics, industry and funders is needed for sustainability.